Indivior PLC (LON:INDV – Get Free Report) shares fell 17% during mid-day trading on Thursday . The stock traded as low as GBX 548.71 ($6.90) and last traded at GBX 720.60 ($9.07). 2,904,792 shares changed hands during mid-day trading, an increase of 294% from the average session volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.92).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 1,800 ($22.65) target price on shares of Indivior in a research note on Tuesday, December 17th.
Check Out Our Latest Research Report on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Business Services Stocks Investing
- Should You Hold Nvidia Stock for the Long Haul or Trade It?
- What is a SEC Filing?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
- What is the Dow Jones Industrial Average (DJIA)?
- Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.